NOVEL STRATEGIES TO IMPROVE LIVER CANCER SURVEILLANCE UPTAKE AND EARLY DETECTION
NOVEL STRATEGIES TO IMPROVE LIVER CANCER SURVEILLANCE UPTAKE AND EARLY DETECTION
批准号:
10457301
负责人:
ANNA S.F. LOK
金额:
$66.54万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-13 至 2024-08-31
关键词:
AbdomenAddressAlgorithmsAreaBenignBindingBiological MarkersBiological Specimen BanksCenter for Translational Science ActivitiesCirrhosisClinicalClinical ResearchComputerized Medical RecordContrast MediaDataDetectionDiagnosisEarly DiagnosisEngineeringEnrollmentFundingGPC3 geneGoalsHealth PersonnelHepatitis CImageIncidenceInformation TechnologyIntestinal DiseasesLabelLaboratoriesLesionLiverLiver diseasesMachine LearningMagnetic Resonance ImagingMalignant - descriptorMalignant Epithelial CellMalignant NeoplasmsMalignant neoplasm of liverMeasurementMedical ImagingMethodsModelingNoduleOrganPancreatic DiseasesPatientsPeptidesPopulations at RiskPrimary Malignant Neoplasm of LiverPrimary carcinoma of the liver cellsProspective StudiesProviderRadiology SpecialtyResearchResourcesRiskScanningScreening for Hepatocellular CancerSensitivity and SpecificitySerumSpecialistSpecific qualifier valueSpecimenSurfaceSystemTestingTimeTissuesUnited StatesUnited States National Institutes of HealthWorkX-Ray Computed Tomographyaccurate diagnosisbaby boomerbasedata repositorydiagnostic accuracydiagnostic tooldiagnostic valueexperiencefollow-upimage processingimaging biomarkerimaging studyimprovednovelnovel strategiespatient screeningpatient stratificationpatient-level barrierspredictive modelingpredictive toolsradiomicsrepositoryresponserisk stratificationsample collectionscreeningstatisticssurveillance imagingsurveillance strategyultrasounduptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
This proposal is submitted in response to RFA-CA-17-025. Hepatocellular carcinoma (HCC) is the most
common primary liver cancer and one of the few cancers with increasing incidence in the United States.
Survival of patients with HCC is poor because most patients are diagnosed at late stages when treatment
options are limited. HCC surveillance can detect cancers early and improve survival but it is inconsistently
implemented. Not all liver nodules detected on surveillance imaging are malignant, these indeterminate
nodules require follow up imaging to determine if they are HCC. This proposal assembles a team of specialists
with complementary expertise in liver diseases, liver cancer, radiology, engineering, statistics, and information
technology. The goals are to: (1) Improve HCC surveillance uptake in patients with cirrhosis by leveraging
electronic medical records to remind healthcare providers and patients when they are due for screening tests;
(2) Leverage analytic morphomics and machine learning to increase the detectability of HCC at an early stage;
and (3) Increase detectability of HCC at an early stage using tagged HCC-specific peptides. We have worked
closely together for many years and have participated/led many NIH funded clinical research networks. We
have expertise and experience to carry out the proposed studies and will collaborate with other centers in the
Liver Center Network to validate the methods/models we develop. We will also enroll patients with cirrhosis
and collect data and specimens and provide access to existing well characterized data and specimen
repositories that include both prevalent and incident HCC for Trans-Network studies. We are confident we will
be able to contribute to this Liver Cancer Network and to early detection of HCC in multiple ways.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
Development and Implementation of a Hepatocellular Carcinoma Surveillance Quality Metric.
肝细胞癌监测质量指标的制定和实施。
DOI:
10.1016/j.cgh.2022.12.009
发表时间:
2023
期刊:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
影响因子:
--
作者:
[Parikh,NeeharD, Dehmlow,Cheryl, Ellies,Tammy, Tapper,ElliotB, Lok,AnnaSF]
通讯作者:
Lok,AnnaSF
DOI:
10.14309/ctg.0000000000000616
发表时间:
2023-10-01
期刊:
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
影响因子:
3.6
作者:
[Mazumder, Nikhilesh R., Enchakalody, Binu, Zhang, Peng, Su, Grace L.]
通讯作者:
Su, Grace L.
DOI:
10.1002/hep4.1768
发表时间:
2021-11
期刊:
Hepatology communications
影响因子:
5.1
作者:
[Zou WY, Enchakalody BE, Zhang P, Shah N, Saini SD, Wang NC, Wang SC, Su GL]
通讯作者:
Su GL
NOVEL STRATEGIES TO IMPROVE LIVER CANCER SURVEILLANCE UPTAKE AND EARLY DETECTION
-
批准号:10229408
-
项目类别:
-
资助金额:$53.0万
-
财政年份:2018
-
负责人:ANNA S.F. LOK
-
依托单位:
Hepatitis B Clinical Research Network Clinical Center: Michigan-Hawaii consortium
-
批准号:8330278
-
项目类别:
-
资助金额:$30.91万
-
财政年份:2008
-
负责人:ANNA S.F. LOK
-
依托单位:
Hepatitis B Clinical Research Network Clinical Center: Michigan-Hawaii consortium
-
批准号:7932179
-
项目类别:
-
资助金额:$36.26万
-
财政年份:2008
-
负责人:ANNA S.F. LOK
-
依托单位:
Hepatitis B Clinical Research Network Clinical Center: Michigan-Hawaii consortium
-
批准号:8139705
-
项目类别:
-
资助金额:$23.55万
-
财政年份:2008
-
负责人:ANNA S.F. LOK
-
依托单位:
Hepatitis B Clinical Research Network Clinical Center: Michigan-Hawaii consortium
-
批准号:7693735
-
项目类别:
-
资助金额:$40.13万
-
财政年份:2008
-
负责人:ANNA S.F. LOK
-
依托单位:
Hepatitis B Clinical Research Network Clinical Center: Michigan - Hawaii Consortium
-
批准号:8975345
-
项目类别:
-
资助金额:$34.45万
-
财政年份:2008
-
负责人:ANNA S.F. LOK
-
依托单位:
Hepatitis B Clinical Research Network Clinical Center: Michigan - Hawaii Consortium
-
批准号:9133357
-
项目类别:
-
资助金额:$23.9万
-
财政年份:2008
-
负责人:ANNA S.F. LOK
-
依托单位:
Hepatitis B Clinical Research Network Clinical Center: Michigan-Hawaii consortium
-
批准号:7578396
-
项目类别:
-
资助金额:$14.32万
-
财政年份:2008
-
负责人:ANNA S.F. LOK
-
依托单位:
Hepatitis B Clinical Research Network Clinical Center: Michigan-Hawaii consortium
-
批准号:8545809
-
项目类别:
-
资助金额:$37.33万
-
财政年份:2008
-
负责人:ANNA S.F. LOK
-
依托单位:
Hepatitis B Clinical Research Network Clinical Center: Michigan - Hawaii Consortium
-
批准号:10057559
-
项目类别:
-
资助金额:$4.72万
-
财政年份:2008
-
负责人:ANNA S.F. LOK
-
依托单位:
Hepatitis B Clinical Research Network Clinical Center: Michigan-Hawaii consortium
-
批准号:8728817
-
项目类别:
-
资助金额:$14.14万
-
财政年份:2008
-
负责人:ANNA S.F. LOK
-
依托单位:
Hepatitis B Clinical Research Network Clinical Center: Michigan - Hawaii Consortium
-
批准号:9354579
-
项目类别:
-
资助金额:$21.65万
-
财政年份:2008
-
负责人:ANNA S.F. LOK
-
依托单位:
INACTIVE CARRIERS OF HEP B VIRUS & HEPB E ANTIGEN-NEG CHRONIC HEPB IN NAMER
-
批准号:7603759
-
项目类别:
-
资助金额:$1.29万
-
财政年份:2007
-
负责人:ANNA S.F. LOK
-
依托单位:
HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT TO PREVENT CIRRHOSIS (HALT-C) TRIAL
-
批准号:7603697
-
项目类别:
-
资助金额:$4.65万
-
财政年份:2007
-
负责人:ANNA S.F. LOK
-
依托单位:
INACTIVE CARRIERS OF HEP B VIRUS & HEPB E ANTIGEN-NEG CHRONIC HEPB IN NAMER
-
批准号:7376590
-
项目类别:
-
资助金额:$3.88万
-
财政年份:2006
-
负责人:ANNA S.F. LOK
-
依托单位:
HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT TO PREVENT CIRRHOSIS (HALT-C) TRIAL
-
批准号:7376494
-
项目类别:
-
资助金额:$15.53万
-
财政年份:2006
-
负责人:ANNA S.F. LOK
-
依托单位:
HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT TO PREVENT CIRRHOSIS (HALT-C) TRIAL
-
批准号:7199803
-
项目类别:
-
资助金额:$19.76万
-
财政年份:2005
-
负责人:ANNA S.F. LOK
-
依托单位:
INACTIVE CARRIERS OF HEP B VIRUS & HEPB E ANTIGEN-NEG CHRONIC HEPB IN NAMER
-
批准号:7199920
-
项目类别:
-
资助金额:$1.18万
-
财政年份:2005
-
负责人:ANNA S.F. LOK
-
依托单位:
Hepatitis C Antiviral Long-term Treatment to Prevent Cirrhosis (HALT-C) Trial
-
批准号:7039754
-
项目类别:
-
资助金额:$26.63万
-
财政年份:2004
-
负责人:ANNA S.F. LOK
-
依托单位:
Factors Associated with Advanced Fibrosis in Patients with Chronic Hepatitis C
-
批准号:7039826
-
项目类别:
-
资助金额:$0.05万
-
财政年份:2004
-
负责人:ANNA S.F. LOK
-
依托单位:
海外基金